medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2005, Number 3

<< Back Next >>

Acta Med 2005; 3 (3)

Positron emission tomography. PET: fundamentals and indications

Altamirano LJ, Estrada SGR, Ramírez AJL

Language: Spanish
References: 77
Page: 179-189
PDF size: 167.27 Kb.


ABSTRACT

Positron emission tomography is the most modern advance in Nuclear Medicine. It is capable to study cellular and metabolically numerous organs. The equipment is composed of three subunits: the cyclotron, the radiopharmaceutical laboratory and the PET scanner. Its clinical applications are neurology, cardiology and oncology. 2-[F-18] fluoro-2-deoxy-D-glucose (18FDG) administered intravenously is the most commonly used radioisotope. The applications of PET in clinical oncology are: differential diagnosis of benign and malignant lesions, staging and restaging, localization of the best place for the node biopsy, grading and prognosis, assessment of regional lymph node involvement or distant metastasis and differentiating areas of radiation necrosis from tumor recurrence. 18F-FDG PET is just the begening in the ongoing development of molecular imaging.


REFERENCES

  1. Phelps ME, Hoffman, EJ, Huang SC, Ter-Pogossian MM. Effect of positron range on spatial resolution. J Nucl Med 1975; 16: 649-652.

  2. Rodríguez M, Asensio C, Gómez MV, Carreras JL, Martín JM. Agencia de Evaluación de Tecnologías Sanitarias (AETS). Instituto de Salud Carlos III-Ministerio de Sanidad y Consumo. “Tomografía por Emisión de Positrones (PET) con 18FDG en Oncología Clínica (Revisión Sistemática)”. Madrid: AETS-Instituto de Salud Carlos III, Noviembre de 2001.

  3. Hamacher K, Coenen HH, Stöcklin G. Efficient stereospecific syntesis of no-carrier-added 2-(18F)-fluoro-2-deoxy-D-glucose using amino-polyether supported nucleophilic substitution. J Nucl Med 1986; 27: 235-238.

  4. Hamacher K, Blessing G, Nebeling B. Computer-aided synthesis (CAS) of no-carrier added 2-(18F)-fluoro-2-deoxyglucose: an efficient automated system for the amino polyether-supported nucleophilic fluorination. Appl J Radiat Isot 1990; 41: 49-65.

  5. Fichman AJ, Alpert NM. FDG-PET in oncology: there’is more to it than looking at pictures (Editorial). J Nucl Med 1993; 34: 6-11.

  6. Haberkorn U, Strauss LG, Dimitrakopoulou A, Engenhart R, Oberdorfer F, Ostertag H et al. PET studies of FDG metabolism in patients with recurrent colorrectal tumors receiving radiotherapy. J Nucl Med 1991; 32: 1485-1490.

  7. Warburg O. On the metabolism of tumors in the body. In: Warburg O. ed. London: Constable and Co. 1930: 75-327.

  8. Minn H, Joensuu H, Ahonen A, Klemi P. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer 1988; 61: 1776-1781.

  9. Slosman DO, Pittet N, Donath A, Polla BS. Fluordeoxyglucose cell incorporation as an index of cell proliferation: evaluation of accuracy in cell culture. Eur J Nucl Med 1993; 20: 1084-1088.

  10. Haberkorn U, Ziegler SI, Oberdorfer F, Strauss LG, Doll J, Van Kaick G. Relation of FDG uptake to proliferation and the expression of glycolysis-associated genes in animal tumor models (Abstract). J Nucl Med 1994; 35: 220P.

  11. Carreras DJL. PET en Oncología. 1ra. Edición. Nova Sidonia. 2002.

  12. Medicare oficial U.S. government site. Department of health and human services. U.S.A.

  13. Hagge RJ, Wong TZ, Coleman RE. Update on nuclear medicine. Positron emission tomography. Brain tumors and lung cancer. Radiol Clin North Am 2001; 39(5): 1587-94.

  14. Lassman AB, DeAngelis LM. Brain metastasis. Neurologic Clinics 2003; 21(1): 733-861.

  15. Quan D, Hackney DB, Pruitt AA, Lenkinski RE, Cecil KM. Transient MRI enhancement in a patient with seizures and previously resected glioma: Use of MRS. Neurology 1999; 53(1): 1593-608.

  16. Matthews PM, Wylezinska M, Cadoux Hudson T. Novel approaches to imaging brain tumors. Hematology Oncology Clinics of North America 2001; 15(4): 1534-602.

  17. Wong TZ, Van der Westhuizen GJ, Coleman RE. Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am 2002; 12(4): 615-26.

  18. Benard F, Romsa J, Hustinx R. Imaging gliomas with positron emission tomography and single photon emission computed tomography. Semi Nucl Med 2003; 33(2): 148-62.

  19. Rozenthal JM, Levine RL, Nickles RJ, Dobkin JA. Glucose uptake by gliomas after treatment. A positron emission tomographic study. Arch Neurol 1989; 46: 1302-1307.

  20. Jarden JO. Treatment of brain tumours investigation by positron emission tomography. Ugeskr Laeger 1996; 158: 4086-4090.

  21. Hoffman JM, Waskin HA, Schifter T. FDG PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med 1993; 34: 567-575.

  22. Scott JN, Brasher PMA, Sevick RJ, Rewcastle NB, Forsyth PA. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 2002; 59(6): 947-9.

  23. Pierce MA, Johnson MD, Maciunas RJ et al. Evaluating contrast-enhancing brain lesions in patients with AIDS by using positron emission tomography. Ann Intern Med 1995; 123: 594-598.

  24. Tian M, Zhang H, Higuchi T, Oriuchi N, Endo K. Oncological diagnosis using (11)C-choline positron emission tomography in comparison with 2-deoxy-2-18F fluoro-D-glucose positron emission tomography. Mol Imaging Biol 2004; 6(3): 172-9.

  25. Menendez J, Lilien D, Nanda A et al. Use of 18FDG for the differentiation of cerebral lesions in patients with acquired immune deficiency syndrome. Neurosurg Focus 2000; 8(2): 80-9.

  26. Langleben DD. PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med 2000; 41(11): 1861-7.

  27. Jiménez VAM, Montz AR, Pérez CMJ, Carreras JL. Tumores del sistema nervioso central. La Tomografía por Emisión de Positrones en Oncología. Ed. Real Academia Nacional de Medicina. ed. Primera. Madrid, España. 2002.

  28. Delbeke D, Martin WH. Update on nuclear medicine. Positron emission tomography imaging in oncology. Radiologic Clinics of North America 2001; 39(5): 2632-75.

  29. Nelson SJ, Day MR, Buffone PJ, Wald LL, Budinger TF, Hawkins R et al. Alignment of volume MR images and high resolution F-18-fluorodeoxyglucose PET images for the evaluation of patients with brain tumours. J Comput Assist Tomogr 1997; 21: 183-191.

  30. Viergever MA, Maintz JB, Niessen WJ, Noordmans HJ, Pluim JP, Stokking R et al. Registration, segmentation, and visualization of multimodal brain images. Comput Med Imaging Graph 2001; 25: 147-151.

  31. Julow J, Major T, Emri M, Valalik I, Sagi S, Mangel L et al. The application of image fusion in stereotactic brachytherapy of brain tumours. Acta Neurochir (Wien) 2000; 142: 1253-1258.

  32. Hanasono MM, Kunda LD, Segall GM, Ku GH, Terris DJ. Uses and limitations of FDG positron emission tomography in patients with head and neck cancer. Laryngoscope 1999; 109: 880-885.

  33. Slevin NJ, Collins CD, Hastings DL, Waller ML, Johnson RJ, Cowan RA, Birzgalis AR, Farrington WT, Swindell R. The diagnostic value of positron emission tomography (PET) with radiolabelled fluoro-deoxyglucose (18F-FDG) in head and neck cancer. J Laryngol Otol 1999; 113: 548-554.

  34. Grunwald F, Kalicke T, Feine U, Lietzenmayer R, Scheidhauser K. 18Fluorine fluorodeoxyglucose, positron emission tomography en thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999; 26(12): 1547-1552.

  35. Brandt-Mainz K, Muller SP, Gorges R. The value of 18fluorine fluorodeoxyglucos PET in patients with medullary thyroid cancer. Europ J Nucl Med 2000; 27(5): 490-496.

  36. Baum RP, Presselt N, Bonnet R. Pulmonary Nodules and Non-Small-Cell Bronchial Carcinoma. PET in Oncology. Basics and Clinical Applications. New York; 1999: 102-119.

  37. Collins BT, Lowe VJ, Dunphy FR. Initial evaluation of pulmonary abnormalities: CT-guided fine-needle aspiration biopsy and 18fluorine fluorodeoxyglucose positron emission tomography correlation. Diagn Cytopathol 2000; 22(2): 92-6.

  38. Gould MK, Lillington GA. Strategy and cost in investigating solitary pulmonary nodules. Chest 1997; 112: 418-22.

  39. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastasis from non small cell lung cancer: mediastinal staging in the 1990 s-meta-analytic comparison of PET and CT. Radiology 1999; 213(2): 530-6.

  40. Coleman RE. PET in lung cancer. J Nucl Med 1999; 40(5): 814-20.

  41. Remge M, Pieterman MD, John WG, Van Putten MD, Jacobus J, Meuzelaar MD. Preoperative staging of non-small-cell lung cancer with positron emission tomography. N Engl J Med 2000; 343: 254-61.

  42. Avril N, Dose J, Janicke F, Ziegler S, Romer W, Weber W et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(18fluorine)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst 1996; 4: 88-2.

  43. Morrow M, Foster R. Staging of breast cancer: a new rationale for internal mammary node biopsy. Arch Surg 1981; 116: 748-50.

  44. Eubank WB, Mankoff DA, Takasugi J, Vesselle H, Eary JF, Shanley TJ, Gralow JR, Charlop A, Ellis GK, Lindsley KL, Austin-Seymour MM, Funkhouser CP, Livingston RB. 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol 2001; 19(15): 3516-23.

  45. Schelling M, Avril N, Nahrig J, Kuhn W, Romer W, Sattler D et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000; 18: 1689-95.

  46. Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000; 18: 1676-88.

  47. Ho CL, Dehdashti F, Griffeth LK. Fdg pet Evaluation of indeterminate pancreatic masses. Comput Assisted Tomogr 1996; 20: 363-369.

  48. Zimny M, Bares R. FASS. Fluorine-18 fluorodeoxiglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma

  49. Keogan MT, Tyler D, Clark L. Diagnosis of pancreatic carcinoma: Role of FDG PET. AJR Am J Roentgenol 1998; 171: 1565-1570.

  50. Delbeke D, Chapman WC, Pinson CW. F-18 Fluorodeoxiglucose imaging with positron emission tomography (FDG_PET) has a significant impact on diagnosis and management of pancreatic ductal carcinoma. J Nucl Med 1999; 40: 1784-1792.

  51. Rose DM, Delbeke D, Beauchamp RD. F18 FDG PET in the management of patients with suspected pancreatic cancer. Ann Surg 1998; 229: 729-738.

  52. Zimny M, Buell U, Diederichs CG. False positive FDG PET in patients with pancreatic masses: an issue of proper patient selection? Eur J Nucle Med 1998; 25: 1352.

  53. Shreve PD. Focal Fluorine-18-fuorodeoxiglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med 1998; 25: 259-264.

  54. Iwata Y, Shiomi S, Sasaki N. Clinical Usefulness of positron emission tomography with F18 –FDG in the diagnosis of the liver tumors. Ann Nucl Med 2000; 14: 121-126.

  55. Trojan J, Shroeder O, Raedle J. F18-FDG PET for imaging of hepatocelullar carcinoma. Am J Gastroenterol 1999; 84: 3314-3319.

  56. Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Ph. Gambihir SS. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000; 41(7): 1177-1189.

  57. Valk PE, Abella-Columna E, Haseman MK, Pounds TR, Tesar RD, Myerss RW. Whole-body PET imaging with 18fluorodeoxyglucose in management of recurrent Colorectal cancer. Arch Surg 1999; 134(5): 503-513.

  58. Hoskin PJ. FDG PET in the management of lymphoma: a clinical perspective. Eur J Nucl Med Mol Imaging 2002; 29(4): 449-451.

  59. Bar-Shalom R, Yefremov N, Guralnik L et al. Clinical performance or PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003; 44(8): 1200-1209.

  60. Kostakoglu L, Goldsmith S. 18F-FDG PET evaluation of the response to therapy for lymphoma, breast, lung and colorectal carcinoma. J Nucl Med 2003; 44(2): 224-239.

  61. Rini J, Leonidas J, Tomas M et al. 18FDF PET versus CT for evaluating the spleen during initial staging of lymphoma. J Nucl Med 2003; 44(7): 1072-1074.

  62. Spaepen K, Stroobants S, Dupont P et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (18F-FDG) after first-line chemotherapy in non-Hodgkin´s lymphoma: is (19F)FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19: 414-419.

  63. Hueltenschmidt B, Sautter-Bihl ML, Lang O, Maul FD, Fischer J, Mergenthaler HG et al. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer 2001; 91: 302-310.

  64. Wahl RL, Kaminski MS, Ethier SP, Hutchins GD. The potential of 2-deoxy-2F(F-18)-D-glucose (FDG) for the detection of tumor involvement in lymph nodes. J Nucl Med 1990; 31: 1831-1834.

  65. Crippa F, Leutner M, Belli F et al. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med 2000; 4: 1491-4.

  66. Tyler DS, Onaitis M, Kherani A et al. Positron emission tomography scanning in malignant melanoma. Cancer 2000; 89: 1019-25.

  67. Eigtved A, Andersson AP, Dahlstrom K et al. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med 2000; 27: 70-5.

  68. Hanasono MM, Kunda LD, Segall GM, Ku GH, Terris DJ. Uses and limitations of FDG positron emission tomography in patients with head and neck cancer. Laryngoscope 1999; 109: 880-885.

  69. Delgado-Bolton RC, Fernández-Pérez C, Pérez-Castejón MJ et al. Clinical utility of FDG-PET in unknown primary tumors. Congreso Anual de la European Association of Nuclear Medicine (EANM), Amsterdam. 2003 (publicado en el Eur J Nucl Med 2003; 30: S227).

  70. Gupta NC, Nicholson P, Bloomfield SM. FDG-PET in the staging work-up of patients with suspected intracranial metastatic tumors. Ann Surg. 1999; 230: 202-206.

  71. Rades D, Kühnel G, Wildfang I, Börner AR, Schmoll HJ, Knapp W. Localized disease in cancer of unknown primary (CUP): The value of positron emission tomography (PET) for individual therapeutic management. Ann Oncol 2001; 12: 1605-1609.

  72. Seltzer MA, Barbaric Z, Belldegrun A, Naitoh J, Dorey F, Phelps ME, Gambhir SS, Hoh CK. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 1999; 162: 1322-1328.

  73. Barnes MN, Grizzle WE, Grubbs CJ, Partridge EE. Paradigms for Primary Prevention of Ovarian Carcinoma. CA Cancer J Clin 2002; 52: 216-225.

  74. Yoshida. FDG-PET Plus CT Aids in Ovarian Cancer Staging. American Journal of Roentgenology 2004; 182(1): 227-233.

  75. Pannu HK, Cohade C, Bristow RE, Fishman EK, Wahl RL. PET-CT detection of abdominal recurrence of ovarian cancer: radiologic-surgical correlation. Radiographics 2004; 24(1): 209-23.

  76. Ryu SY, Kim MH, Choi SC, Choi CW, Lee KH. Detection of early recurrence with 18F-FDG PET in patients with cervical cancer. J Nucl Med 2003; 44(3): 347-52.

  77. Havrilesky LJ, Wong TZ, Secord AA, Berchuck A, Clarke-Pearson DL, Jones EL. The role of PET scanning in the detection of recurrent cervical cancer. Gynecol Oncol 2003; 90(7): 186-90.




2020     |     www.medigraphic.com